Aflibercept biosimilar (Momenta/Mylan)

阿柏西普生物类似药（Momenta/Mylan）

Report date: 2024/05/27 17:19:52

Base Information

Drug NameAflibercept biosimilar (Momenta/Mylan)
Drug Alias NameAflibercept-jbvf阿柏西普生物仿制药（Momenta/Mylan）YESAFILIM-710MYL-1701P
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[7] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/09/15
Country/TerritoryUnited StatesIndiaEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMylan NvMomenta
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics IncMylan Pharmaceuticals IncMomenta Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX44S01LA05
Related LinksN/A